Medigen Biotechnology Corp. announced that the Ministry of Health and Welfare has approved the collaborative autologous Gamma-Delta T cell therapy project by the Company and Changhua Christian Hospital.
Cause of occurrence: Medigen, in collaboration with Changhua Christian Medical Foundation Changhua Christian Hospital, has applied for the Autologous Gamma-Delta T Cell (Magicell-GDT) cell therapy project. On February 16, 2024, Medigen received the approval letter from the competent authority, the Ministry of Health and Welfare, confirming that Medigen's Cell Processing Unit is compliant with Good Tissue Practice (GTP). In accordance with the regulations of the ?Regulations Governing the Application of Specific Medical Examination Technique and Medical Device?, the Magicell-GDT cells produced at Medigen?s Cell Processing Unit can be used for treating stage IV solid tumors at Changhua Christian Hospital. Countermeasures: The announcement was released in accordance with the approval letter of the Ministry of Health and Welfare. Any other matters that need to be specified: Details on the approved items in the abovementioned Changhua Christian Hospital cell therapy project: A. Type of cell therapy: Autologous Gamma-Delta T cell (Magicell-GDT) B. Indication: Stage IV solid tumor; Lung cancer, breast cancer, kidney cancer, prostate cancer, pancreatic cancer, colorectal cancer, gastric cancer. C. Cell processing unit: Medigen?s cell processing unit.